Stock Quote
Nektar Therapeutics (NKTR.O) (Nasdaq)
$8.69
2:53pm EST
+0.58%
$8.64
$8.76
449,057
$8.77
$8.59
$10.64
$3.51
0.23
489,904
NKTR.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Chess, Robert | Chairman of the Board | 1,468,750 |
| Robin, Howard | President, Chief Executive Officer, Director | 2,149,090 |
| Nicholson, John | Chief Financial Officer, Senior Vice President | 1,309,800 |
Profile
Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Company’s product pipeline is comprised of drug... Full Description
Company Address
Nektar Therapeutics
201 Industrial Road
San Carlos CA 94070
P: +1650.6313100
F: +1650.6313150
201 Industrial Road
San Carlos CA 94070
P: +1650.6313100
F: +1650.6313150
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| The Dow Chemical Company | $28.06 | +0.13 |
| Enzon Pharmaceuticals, Inc. | $10.30 | -0.02 |
| Neose Technologies, Inc. | $0.08 | 0.00 |
| NKTR.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 13.14 | 29.90 |
| ROI(TTM) | -3.91 | 2.35 |
| ROE(TTM) | -16.82 | 3.59 |
| Consensus Recommendation | Buy |
|---|---|
| EPS Est. (Current Period) | -0.15 |
| EPS Est. (Current Year) | -0.80 |
| Total Revenue | $10.22M |
| Net Income | $-30.97M |
| EPS | $-0.33 |
